Ser364
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser364  -  JIP3 (human)

Site Information
TRLDRtGssPTQGIV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2025497

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 4 ) , mass spectrometry ( 1 , 2 , 3 ) , mass spectrometry (in vitro) ( 4 ) , western blotting ( 4 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 2 , 3 ) , non-small cell lung cancer ( 3 ) , non-small cell lung adenocarcinoma ( 2 ) , cancer, squamous cell carcinoma ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ROCK1 (human) ( 4 )
Kinases, in vitro:
ROCK1 (human) ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

3

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

4

Ongusaha PP, et al. (2008) Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal 1, ra14
19036714   Curated Info